{"organizations": [], "uuid": "aa1ab39e29b4c6732c6c26568e0d731a73ee2066", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180523.html", "section_title": "Archive News &amp; Video for Wednesday, 23 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-receives-com/brief-cosmo-pharmaceuticals-receives-complete-response-letter-from-fda-on-methylene-blue-mmx-nda-idUSFWN1SU08C", "country": "US", "domain_rank": 408, "title": "BRIEF-Cosmo Pharmaceuticals Receives Complete Response Letter From FDA On Methylene Blue MMX NDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.135, "site_type": "news", "published": "2018-05-23T13:11:00.000+03:00", "replies_count": 0, "uuid": "aa1ab39e29b4c6732c6c26568e0d731a73ee2066"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cosmo-pharmaceuticals-receives-com/brief-cosmo-pharmaceuticals-receives-complete-response-letter-from-fda-on-methylene-blue-mmx-nda-idUSFWN1SU08C", "ord_in_thread": 0, "title": "BRIEF-Cosmo Pharmaceuticals Receives Complete Response Letter From FDA On Methylene Blue MMX NDA", "locations": [], "entities": {"persons": [{"name": "methyle", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "fda on methylene blue mmx nda", "sentiment": "negative"}, {"name": "cosmo", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "cosmo pharmaceuticals", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 23 (Reuters) - COSMO PHARMACEUTICALS NV:\n* RECEIVES COMPLETE RESPONSE LETTER FROM FDA ON METHYLENE BLUE MMX NDA\n* FDA DID NOT RAISE ANY SAFETY OR MANUFACTURING CONCERN * COSMO PHARMACEUTICALS - FDA DETERMINED IT CAN’T APPROVE NDA IN ITS PRESENT FORM, PROVIDES RECOMMENDATIONS NEEDED FOR RESUBMISSION\n* DOES NOT EXPECT ITS GUIDANCE FOR 2018 TO CHANGE AT THIS POINT IN TIME\n* FDA IDENTIFIED UNSPECIFIED DEFICIENCIES THAT PRECLUDE CONTINUATION OF DISCUSSION OF LABELING AND POST-MARKETING REQUIREMENT/COMMITMENTS\n* COSMO PHARMACEUTICALS THERE MIGHT NOT BE METHYLENE BLUE MMX REVENUES IN THIS YEAR, THERE ALSO WON’T BE ASSOCIATED PRODUCT LAUNCH AND SALES FORCE COSTS\n* COSMO PHARMACEUTICALS - BELIEVES CONCERNS RAISED BY FDA ARE FULLY ADDRESSABLE, WILL WORK TO HAVE MEETING WITH FDA AS QUICK AS POSSIBLE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-23T13:11:00.000+03:00", "crawled": "2018-05-24T20:24:12.006+03:00", "highlightTitle": ""}